Company news
Theralink Technologies Inc. (OTC:THER) news
Theralink Technologies Inc. news releases on 6ix. Latest, Mar 13, 2017: OncBioMune Acquires Vitel Laboratorios, Gains Two Revenue Generating Drugs, Robust…
Press releases — page 2
OncBioMune Acquires Vitel Laboratorios, Gains Two Revenue Generating Drugs, Robust Pipeline and Extensive Distribution Network
March 13, 2017
OncBioMune Announces Cancer Vaccine Poster Presentation at the 2017 American Association for Cancer Research Meeting
February 2, 2017
Latest Clinical Data from OncBioMune Supports Safety and Therapeutic Profile of ProscaVax for Prostate Cancer for Upcoming Phase 2 Clinical Trials
January 26, 2017
Departments of Urology and Oncology Approve Protocol for OncBioMune's Phase 2/3 Trial of ProscaVax for Prostate Cancer in Mexico
January 18, 2017
OncBioMune Submitting Clinical Trial of World's First Early-Stage Prostate Cancer Vaccine to The Cancer Therapy Evaluation Program (CTEP) at the National Cancer Institute
January 10, 2017
Patients Pre-Screened for OncBioMune Pharmaceuticals Phase 2/3 Trial of ProscaVax for Prostate Cancer
December 28, 2016
OncBioMune Awarded Patent in Europe Protecting Novel Cancer Vaccine Technology
December 12, 2016
OncBioMune and the Clinical Trial Investigators Have Agreed Upon the Protocol for Their Phase 2 Trial of Novel Vaccine for Early Stage Prostate Cancer
December 8, 2016
OncBioMune Provides Update on Acquisition of Vitel Laboratorios
December 7, 2016
OncBioMune Broadens Portfolio, Partners and Product with Vitel Acquisition
November 11, 2016
OncBioMune Signs Term Sheet to Acquire Vitel Laboratorios, S.A. de C.V.
November 3, 2016
Immunotherapy Expert Dr. Brian Barnett Joins OncBioMune Scientific Advisory Board
October 24, 2016
OncBioMune Receives Notice of Patent Allowance for Novel Cancer Vaccine ProscaVax(TM) in Mexico
October 19, 2016
OncBioMune Pharmaceuticals Announces Shareholder Update
October 7, 2016
OncBioMune CEO Dr. Jonathan Head to Present Abstract on Prostate Cancer Vaccine at Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science Into Survival
September 27, 2016
New Study Opens Window for OncBioMune Cancer Vaccine in Early and Advanced Prostate Cancer Patients
September 27, 2016
Prostate Cancer Free for 10 Years, Stephen Karalekas Thanks OncBioMune for ProscaVax in Testimonial Video
September 21, 2016
OncBioMune Pharmaceuticals in Discussions to Acquire Vitel Laboratorios, S.A. de C.V.
September 14, 2016
Latest Data From Phase 1 Trial of ProscaVax for Prostate Cancer Reinforces Safety and Benefit of Novel Cancer Vaccine
August 8, 2016
Pre-Clinical Research Supports Additional Studies of OncBioMune Technology for Breast Cancer Vaccine
July 20, 2016
OncBioMune Submits Protocol to Initiate Phase 2/3 Trial of ProscaVax for Prostate Cancer
July 13, 2016
OncBioMune Research Shows Activity of PGT Technology in a Mammary Cancer Animal Model
July 6, 2016
OncBioMune Provides Corporate Update; ASCO Reinforces Market Opportunity for New Prostate Cancer Vaccine as Phase 2 Trial Approaches
June 14, 2016
OncBioMune Phase 2 Prostate Cancer Trial in Mexico Key to Expedited Commercialization
June 3, 2016
Mexican Regulatory Authorities Supportive of OncBioMune's Phase 2 of ProscaVax for Prostate Cancer
June 2, 2016
OncBioMune Receives Patent on Paclitaxel-Gallium-Transferrin for Targeted Cancer Treatment
May 24, 2016
Celldex Stumble Makes Space for OncBioMune at Head of Cancer Vaccines
May 12, 2016
OncBioMune Provides Update on Phase 2 Clinical Trials of ProscaVax for Prostate Cancer
May 11, 2016
OncBioMune Submits Protocol to Principal Investigators for Two Phase 2 Clinical Trials of ProscaVax for Prostate Cancer
May 4, 2016
OncBioMune Receives Notice of Patent Allowance for Cancer Vaccine ProscaVax(R) in China
April 28, 2016
OncBioMune Enters Joint Venture, Preparation for Phase 2 Trial of Novel Cancer Vaccine for Prostate Cancer Underway
April 20, 2016
OncBioMune Receives Notice of Patent Allowance for Cancer Vaccine ProscaVax(R) in Hong Kong
April 12, 2016
OncBioMune Pharmaceuticals Inc Signs MOU for Joint Venture With Vitel Laboratorios to Develop Novel Cancer Vaccine for Mexico and Latin America
March 29, 2016
Dr. J. Jacques Carter Joins OncBioMune Pharmaceuticals Scientific Advisory Board
March 22, 2016
OncBioMune Receives Notice of Patent Allowance for Cancer Vaccine ProscaVax(TM) in Europe
March 16, 2016
OncBioMune Continuing Phase 1 Trial, While Initiating Phase 2 Trial of ProscaVax for Prostate Cancer
February 23, 2016
OncBioMune Invites Shareholders to Join Live Webcast Today at BIO CEO & Investors Conference
February 9, 2016
OncBioMune to Present at 18th Annual BIO CEO & Investors Conference
January 25, 2016
OncBioMune Receives Notice of Allowance for Patent Covering New Targeted Cancer Treatments
January 22, 2016
OncBioMune Adds Capital Markets Leader Daniel Hoverman to Board of Directors
January 5, 2016
OncBioMune Selected to Present at Biotech Showcase 2016
December 16, 2015
OncBioMune Pharmaceuticals Appoints Charles L. Rice, Jr. to Board of Directors
December 3, 2015
OncBioMune Receives Notice of Patent Allowance for Cancer Vaccine ProscaVax(TM) in China and Ukraine
November 10, 2015
OncBioMune Pharmaceuticals Enters Into Common Stock Purchase Agreement With Lincoln Park Capital Fund
October 29, 2015
OncBioMune Presents Data on Novel Cancer Vaccine ProscaVax at International Cancer Immunotherapy Conference
October 9, 2015
OncBioMune Approved for Trading on OTCQB
October 2, 2015
OTC Markets Group Welcomes Newly Verified OTCQB Companies – October 2
October 2, 2015
OncBioMune Pharmaceuticals Begins Trading Under Ticker OBMP
September 29, 2015